Breast Cancer Screening in Women at Higher Than Average Risk: Recommendations from The

Breast Cancer Screening in Women at Higher than Average Risk: Recommendations from the American College of Radiology

REFERENCES

1.Tabár L, Vitak B, Chen TH-H, Yen AM-F, Cohen A, Tot T, et al. Swedish Two-County Trial: Impact of Mammographic Screening on Breast Cancer Mortality during 3 Decades. Radiology. 2011;260(3):658-63.

2.Coldman A, Phillips N, Wilson C, Decker K, Chiarelli AM, Brisson J, et al. Pan-Canadian Study of Mammography Screening and Mortality from Breast Cancer. JNCI Journal of the National Cancer Institute. 2014;106(11):dju261-dju.

3.Duffy SW, Tabár L, Chen H-H, Holmqvist M, Yen M-F, Abdsalah S, et al. The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer. 2002;95(3):458-69.

4.Monticciolo DL, Newell MS, Hendrick RE, Helvie MA, Moy L, Monsees B, et al. Breast Cancer Screening for Average-Risk Women: Recommendations From the ACR Commission on Breast Imaging. J Am Coll Radiol. 2017;14(9):1137-43.

5.Bevers TB, Helvie MA, Bonaccio E, Calhoun KE, Daly MB, Farrar WB, et al. NCCN Guidelines version 1.2017 Breast Cancer Screening and Diagnosis: 2017

6.

7.Mainiero MB, Lourenco A, Mahoney MC, Newell MS, Bailey L, Barke LD, et al. ACR Appropriateness Criteria Breast Cancer Screening. Journal of the American College of Radiology. 2016;13(11):R45-R9.

8.Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996;77(11):2318-24.

9.Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography. CA: A Cancer Journal for Clinicians. 2007;57(2):75-89.

10.Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nature Reviews Cancer. 2004;4(9):665-76.

11.Ford D, Easton DF, Stratton M, Narod SA, Goldgar DE, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62(3):676-89.

12.Frey MK, Sandler G, Sobolev R, Kim SH, Chambers R, Bassett RY, et al. Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non- BRCA cancer-associated genes. Gynecologic Oncology. 2017;146(1):123-8.

13.Bhatia S, Yasui Y, Robison LL, Birch JM, Bogue MK, Diller L, et al. High Risk of Subsequent Neoplasms Continues With Extended Follow-Up of Childhood Hodgkin’s Disease: Report From the Late Effects Study Group. Journal of Clinical Oncology. 2003;21(23):4386-94.

14.Kenney LB, Yasui Y, Inskip PD, Hammond S, Neglia JP, Mertens AC, et al. Breast Cancer after Childhood Cancer: A Report from the Childhood Cancer Survivor Study. Annals of Internal Medicine. 2004;141(8):590-7.

15.Travis LB, Hill D, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, et al. Cumulative Absolute Breast Cancer Risk for Young Women Treated for Hodgkin Lymphoma. JNCI Journal of the National Cancer Institute. 2005;97(19):1428-37.

16.Mulder RL, Kremer LCM, Hudson MM, Bhatia S, Landier W, Levitt G, et al. Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. The Lancet Oncology. 2013;14(13):e621-e9.

17.Metcalfe K, Lubinski J, Lynch HT, Ghadirian P, Foulkes WD, Kim-Sing C, et al. Family History of Cancer and Cancer Risks in Women with BRCA1 or BRCA2 Mutations. JNCI Journal of the National Cancer Institute. 2010;102(24):1874-8.

18.Mariscotti G, Belli P, Bernardi D, Brancato B, Calabrese M, Carbonaro LA, et al. Mammography and MRI for screening women who underwent chest radiation therapy (lymphoma survivors): recommendations for surveillance from the Italian College of Breast Radiologists by SIRM. Radiol Med. 2016;121(11):834-7.

19.Group EC, Darby S, McGale P, al. e. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. The Lancet. 2011;378(9804):1707-16.

20.Fowble B, Hanlon A, Freedman G, Nicolaou N, Anderson P. Second cancers after conservative surgery and radiation for stages I–II breast cancer: identifying a subset of women at increased risk. International Journal of Radiation Oncology*Biology*Physics. 2001;51(3):679-90.

21.Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. The Lancet Oncology. 2010;11(12):1135-41.

22.Dubsky PC, Jakesz R, Mlineritsch B, Pöstlberger S, Samonigg H, Kwasny W, et al. Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group. Journal of Clinical Oncology. 2012;30(7):722-8.

23.Jin H, Tu D, Zhao N, Shepherd LE, Goss PE. Longer-Term Outcomes of Letrozole Versus Placebo After 5 Years of Tamoxifen in the NCIC CTG MA.17 Trial: Analyses Adjusting for Treatment Crossover. Journal of Clinical Oncology. 2012;30(7):718-21.

24.Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. The Lancet Oncology. 2011;12(12):1101-8.

25.Punglia RS, Hassett MJ. Using lifetime risk estimates to recommend magnetic resonance imaging screening for breast cancer survivors. J Clin Oncol. 2010;28(27):4108-10.

26.Arpino G, Laucirica R, Elledge RM. Premalignant and In Situ Breast Disease: Biology and Clinical Implications. Annals of Internal Medicine. 2005;143(6):446.

27.Dupont WD, Page DL. Risk Factors for Breast Cancer in Women with Proliferative Breast Disease. New England Journal of Medicine. 1985;312(3):146-51.

28.Menes TS, Kerlikowske K, Lange J, Jaffer S, Rosenberg R, Miglioretti DL. Subsequent Breast Cancer Risk Following Diagnosis of Atypical Ductal Hyperplasia on Needle Biopsy. JAMA Oncology. 2017;3(1):36.

29. 2017

30.Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, Colditz GA. Meta-Analysis of Survival in African American and White American Patients With Breast Cancer: Ethnicity Compared With Socioeconomic Status. Journal of Clinical Oncology. 2006;24(9):1342-9.

31.DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017.

32.Hunt BR, Hurlbert MS. Black:white disparities in breast cancer mortality in the 50 largest cities in the United States, 2005–2014. Cancer Epidemiology. 2016;45:169-73.

33.Fedewa SA, Ward EM, Stewart AK, Edge SB. Delays in Adjuvant Chemotherapy Treatment Among Patients With Breast Cancer Are More Likely in African American and Hispanic Populations: A National Cohort Study 2004-2006. Journal of Clinical Oncology. 2010;28(27):4135-41.

34.Gorin SS. Delays in Breast Cancer Diagnosis and Treatment by Racial/Ethnic Group. Archives of Internal Medicine. 2006;166(20):2244.

35.Livaudais JC, Hershman DL, Habel L, Kushi L, Gomez SL, Li CI, et al. Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer. Breast Cancer Research and Treatment. 2011;131(2):607-17.

36.McGee SA, Durham DD, Tse CK, Millikan RC. Determinants of Breast Cancer Treatment Delay Differ for African American and White Women. Cancer Epidemiology Biomarkers & Prevention. 2013;22(7):1227-38.

37.Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong Y-N, Edge SB, et al. Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. Journal of Clinical Oncology. 2015;33(20):2254-61.

38.Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in Breast Cancer Stage at Diagnosis and Cancer-Specific Survival by Race and Ethnicity in the United States. JAMA. 2015;313(2):165.

39.Amirikia KC, Mills P, Bush J, Newman LA. Higher population-based incidence rates of triple-negative breast cancer among young African-American women. Cancer. 2011;117(12):2747-53.

40.Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA, et al. Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. JNCI: Journal of the National Cancer Institute. 2015;107(6).

41.Newman LA, Kaljee LM. Health Disparities and Triple-Negative Breast Cancer in African American Women. JAMA Surgery. 2017;152(5):485.

42.Hall MJ, Reid JE, Burbidge LA, Pruss D, Deffenbaugh AM, Frye C, et al. BRCA1andBRCA2mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer. 2009;115(10):2222-33.

43.Churpek JE, Walsh T, Zheng Y, Moton Z, Thornton AM, Lee MK, et al. Inherited predisposition to breast cancer among African American women. Breast Cancer Research and Treatment. 2014;149(1):31-9.

44.D'Orsi C, Sickles EA, Mendelson E, Morris E. ACR BI-RADS Atlas, Breast Imaging Reporting and Data System. 5th edition ed. Reston, VA: American College of Radiology; 2013.

45.Nicholson BT, LoRusso AP, Smolkin M, Bovbjerg VE, Petroni GR, Harvey JA. Accuracy of Assigned BI-RADS Breast Density Category Definitions. Academic Radiology. 2006;13(9):1143-9.

46.Bakic PR, Carton A-K, Kontos D, Zhang C, Troxel AB, Maidment ADA. Breast Percent Density: Estimation on Digital Mammograms and Central Tomosynthesis Projections. Radiology. 2009;252(1):40-9.

47.Martin KE, Helvie MA, Zhou C, Roubidoux MA, Bailey JE, Paramagul C, et al. Mammographic Density Measured with Quantitative Computer-aided Method: Comparison with Radiologists' Estimates and BI-RADS Categories. Radiology. 2006;240(3):656-65.

48.Sprague BL, Gangnon RE, Burt V, Trentham-Dietz A, Hampton JM, Wellman RD, et al. Prevalence of Mammographically Dense Breasts in the United States. JNCI: Journal of the National Cancer Institute. 2014;106(10).

49.Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, et al. Prevention of Breast Cancer in Postmenopausal Women: Approaches to Estimating and Reducing Risk. JNCI Journal of the National Cancer Institute. 2009;101(6):384-98.

50.Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, et al. Validation Studies for Models Projecting the Risk of Invasive and Total Breast Cancer Incidence. JNCI Journal of the National Cancer Institute. 1999;91(18):1541-8.

51.Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined Annually. JNCI Journal of the National Cancer Institute. 1989;81(24):1879-86.

52.Spiegelman D, Colditz GA, Hunter D, Hertzmark E. Validation of the Gail et al. Model for Predicting Individual Breast Cancer Risk. JNCI Journal of the National Cancer Institute. 1994;86(8):600-7.

53.Matsuno RK, Costantino JP, Ziegler RG, Anderson GL, Li H, Pee D, et al. Projecting Individualized Absolute Invasive Breast Cancer Risk in Asian and Pacific Islander American Women. JNCI: Journal of the National Cancer Institute. 2011;103(12):951-61.

54.Parmigiani G, Berry DA, Aguilar O. Determining Carrier Probabilities for Breast Cancer–Susceptibility Genes BRCA1 and BRCA2. The American Journal of Human Genetics. 1998;62(1):145-58.

55.Amir E, Freedman OC, Seruga B, Evans DG. Assessing Women at High Risk of Breast Cancer: A Review of Risk Assessment Models. JNCI Journal of the National Cancer Institute. 2010;102(10):680-91.

56.Kurian AW, Gong GD, John EM, Miron A, Felberg A, Phipps AI, et al. Performance of Prediction Models for BRCA Mutation Carriage in Three Racial/Ethnic Groups: Findings from the Northern California Breast Cancer Family Registry. Cancer Epidemiology Biomarkers & Prevention. 2009;18(4):1084-91.

57.Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Statistics in Medicine. 2004;23(7):1111-30.

58.Antoniou AC, Pharoah PPD, Smith P, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. British Journal of Cancer. 2004.

59.Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer. 1994;73(3):643-51.

60.Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2012. CA: A Cancer Journal for Clinicians. 2012;62(2):129-42.

61.Meads C, Ahmed I, Riley RD. A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance. Breast Cancer Research and Treatment. 2011;132(2):365-77.

62.Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. Journal of Medical Genetics. 2003;40(11):807-14.

63.Quante AS, Whittemore AS, Shriver T, Strauch K, Terry MB. Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance. Breast Cancer Research. 2012;14(6).

64.Brentnall AR, Evans DG, Cuzick J. Distribution of breast cancer risk from SNPs and classical risk factors in women of routine screening age in the UK. British Journal of Cancer. 2014;110(3):827-8.

65.Warwick J, Birke H, Stone J, Warren RML, Pinney E, Brentnall AR, et al. Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I. Breast Cancer Research. 2014;16(5).

66.Broeders M, Moss S, Nyström L, Njor S, Jonsson H, Paap E, et al. The Impact of Mammographic Screening on Breast Cancer Mortality in Europe: A Review of Observational Studies. Journal of Medical Screening. 2012;19(1_suppl):14-25.

67.Nickson C, Mason KE, English DR, Kavanagh AM. Mammographic Screening and Breast Cancer Mortality: A Case-Control Study and Meta-analysis. Cancer Epidemiology Biomarkers & Prevention. 2012;21(9):1479-88.

68.Oeffinger KC, Fontham ETH, Etzioni R, Herzig A, Michaelson JS, Shih Y-CT, et al. Breast Cancer Screening for Women at Average Risk. JAMA. 2015;314(15):1599.

69.Tabár L, Yen AM-F, Wu WY-Y, Chen SL-S, Chiu SY-H, Fann JC-Y, et al. Insights from the Breast Cancer Screening Trials: How Screening Affects the Natural History of Breast Cancer and Implications for Evaluating Service Screening Programs. The Breast Journal. 2014;21(1):13-20.

70.Armes JE, Egan AJM, Southey MC, Dite GS, McCredie MRE, Giles GG, et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations. Cancer. 1998;83(11):2335-45.

71.Carney PA, Miglioretti DL, Yankaskas BC, Kerlikowske K, Rosenberg R, Rutter CM, et al. Individual and Combined Effects of Age, Breast Density, and Hormone Replacement Therapy Use on the Accuracy of Screening Mammography. Annals of Internal Medicine. 2003;138(3):168.

72.Dent R, Warner E. Screening for Hereditary Breast Cancer. Seminars in Oncology. 2007;34(5):392-400.

73.Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, et al. Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer. 1996;77(4):697-709.

74.Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, et al. Contralateral Breast Cancer inBRCA1andBRCA2Mutation Carriers. Journal of Clinical Oncology. 2004;22(12):2328-35.

75.Kriege M, Brekelmans CTM, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, et al. Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition. New England Journal of Medicine. 2004;351(5):427-37.

76.Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, et al. Mammography, Breast Ultrasound, and Magnetic Resonance Imaging for Surveillance of Women at High Familial Risk for Breast Cancer. Journal of Clinical Oncology. 2005;23(33):8469-76.

77.Lehman CD. Role of MRI in screening women at high risk for breast cancer. Journal of Magnetic Resonance Imaging. 2006;24(5):964-70.

78.Lord SJ, Lei W, Craft P, Cawson JN, Morris I, Walleser S, et al. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. European Journal of Cancer. 2007;43(13):1905-17.

79.Sardanelli F, Podo F, Santoro F, Manoukian S, Bergonzi S, Trecate G, et al. Multicenter Surveillance of Women at High Genetic Breast Cancer Risk Using Mammography, Ultrasonography, and Contrast-Enhanced Magnetic Resonance Imaging (the High Breast Cancer Risk Italian 1 Study). Investigative Radiology. 2011;46(2):94-105.

80.Weaver DL, Rosenberg RD, Barlow WE, Ichikawa L, Carney PA, Kerlikowske K, et al. Pathologic findings from the Breast Cancer Surveillance Consortium. Cancer. 2006;106(4):732-42.

81.Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 2012;307(13):1394-404.

82.Brekelmans CTM, Seynaeve C, Bartels CCM, Tilanus-Linthorst MMA, Meijers-Heijboer EJ, Crepin CMG, et al. Effectiveness of Breast Cancer Surveillance inBRCA1/2Gene Mutation Carriers and Women With High Familial Risk. Journal of Clinical Oncology. 2001;19(4):924-30.

83.Komenaka IK, Ditkoff B-A, Joseph K-A, Russo D, Gorroochurn P, Ward M, et al. The development of interval breast malignancies in patients withBRCA mutations. Cancer. 2004;100(10):2079-83.

84.Robson M, Offit K. Management of an Inherited Predisposition to Breast Cancer. New England Journal of Medicine. 2007;357(2):154-62.

85.Scheuer L, Kauff N, Robson M, Kelly B, Barakat R, Sataqopan J, et al. Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers. Journal of Clinical Oncology. 2002;20(5):1260-8.

86.Vasen HFA, Tesfay E, Boonstra H, Mourits MJE, Rutgers E, Verheyen R, et al. Early detection of breast and ovarian cancer in families with BRCA mutations. European Journal of Cancer. 2005;41(4):549-54.

87.Kerlikowske K, Hubbard RA, D.L. M, Geller BM, Yankaskas BC, Lehman CD, et al. Comparative Effectiveness of Digital Versus Film-Screen Mammography in Community Practice in the United States. Annals of Internal Medicine. 2011;155(8):493-502.

88.Carney PA, Miglioretti DL, Yankaskas BC, Kerlikowske K, Rosenberg R, Rutter CM, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med. 2003;138(3):168-75.

89.Bernardi D, Caumo F, Macaskill P, Ciatto S, Pellegrini M, Brunelli S, et al. Effect of integrating 3D-mammography (digital breast tomosynthesis) with 2D-mammography on radiologists’ true-positive and false-positive detection in a population breast screening trial. European Journal of Cancer. 2014;50(7):1232-8.

90.Caumo F, Bernardi D, Ciatto S, Macaskill P, Pellegrini M, Brunelli S, et al. Incremental effect from integrating 3D-mammography (tomosynthesis) with 2D-mammography: Increased breast cancer detection evident for screening centres in a population-based trial. The Breast. 2014;23(1):76-80.

91.Ciatto S, Houssami N, Bernardi D, Caumo F, Pellegrini M, Brunelli S, et al. Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study. The Lancet Oncology. 2013;14(7):583-9.

92.Friedewald SM, Rafferty EA, Rose SL, Durand MA, Plecha DM, Greenberg JS, et al. Breast Cancer Screening Using Tomosynthesis in Combination With Digital Mammography. JAMA. 2014;311(24):2499.

93.Greenberg JS, Javitt MC, Katzen J, Michael S, Holland AE. Clinical Performance Metrics of 3D Digital Breast Tomosynthesis Compared With 2D Digital Mammography for Breast Cancer Screening in Community Practice. American Journal of Roentgenology. 2014;203(3):687-93.

94.Houssami N, Macaskill P, Bernardi D, Caumo F, Pellegrini M, Brunelli S, et al. Breast screening using 2D-mammography or integrating digital breast tomosynthesis (3D-mammography) for single-reading or double-reading – Evidence to guide future screening strategies. European Journal of Cancer. 2014;50(10):1799-807.

95.Lei J, Yang P, Zhang L, Wang Y, Yang K. Diagnostic accuracy of digital breast tomosynthesis versus digital mammography for benign and malignant lesions in breasts: a meta-analysis. European Radiology. 2013;24(3):595-602.

96.McCarthy AM, Kontos D, Synnestvedt M, Tan KS, Heitjan DF, Schnall M, et al. Screening Outcomes Following Implementation of Digital Breast Tomosynthesis in a General-Population Screening Program. JNCI: Journal of the National Cancer Institute. 2014;106(11).

97.Rafferty EA, Park JM, Philpotts LE, Poplack SP, Sumkin JH, Halpern EF, et al. Assessing Radiologist Performance Using Combined Digital Mammography and Breast Tomosynthesis Compared with Digital Mammography Alone: Results of a Multicenter, Multireader Trial. Radiology. 2013;266(1):104-13.

98.Rafferty EA, Park JM, Philpotts LE, Poplack SP, Sumkin JH, Halpern EF, et al. Diagnostic Accuracy and Recall Rates for Digital Mammography and Digital Mammography Combined With One-View and Two-View Tomosynthesis: Results of an Enriched Reader Study. American Journal of Roentgenology. 2014;202(2):273-81.

99.Rose SL, Tidwell AL, Ice MF, Nordmann AS, Sexton R, Song R. A Reader Study Comparing Prospective Tomosynthesis Interpretations with Retrospective Readings of the Corresponding FFDM Examinations. Academic Radiology. 2014;21(9):1204-10.

100.Skaane P, Bandos AI, Gullien R, Eben EB, Ekseth U, Haakenaasen U, et al. Prospective trial comparing full-field digital mammography (FFDM) versus combined FFDM and tomosynthesis in a population-based screening programme using independent double reading with arbitration. European Radiology. 2013;23(8):2061-71.

101.Skaane P, Bandos AI, Gullien R, Eben EB, Ekseth U, Haakenaasen U, et al. Comparison of Digital Mammography Alone and Digital Mammography Plus Tomosynthesis in a Population-based Screening Program. Radiology. 2013;267(1):47-56.

102.Svahn TM, Chakraborty DP, Ikeda D, Zackrisson S, Do Y, Mattsson S, et al. Breast tomosynthesis and digital mammography: a comparison of diagnostic accuracy. The British Journal of Radiology. 2012;85(1019):e1074-e82.

103.Conant EF, Beaber EF, Sprague BL, Herschorn SD, Weaver DL, Onega T, et al. Breast cancer screening using tomosynthesis in combination with digital mammography compared to digital mammography alone: a cohort study within the PROSPR consortium. Breast Cancer Research and Treatment. 2016;156(1):109-16.

104.Haas BM, Kalra V, Geisel J, Raghu M, Durand M, Philpotts LE. Comparison of Tomosynthesis Plus Digital Mammography and Digital Mammography Alone for Breast Cancer Screening. Radiology. 2013:130307.

105.Rafferty EA, Durand MA, Conant EF, Copit DS, Friedewald SM, Plecha DM, et al. Breast Cancer Screening Using Tomosynthesis and Digital Mammography in Dense and Nondense Breasts. JAMA. 2016;315(16):1784.

106.Rafferty EA, Rose SL, Miller DP, Durand MA, Conant EF, Copit DS, et al. Effect of age on breast cancer screening using tomosynthesis in combination with digital mammography. Breast Cancer Research and Treatment. 2017;164(3):659-66.